Thomson PharmaSM - Integration enhances communication
Thomson Scientific, part of the Thomson Corporation, is a global leader in providing integrated information solutions to professionals working at all stages of the drug lifecycle. For decades, we have provided authoritative content to the Pharmaceutical and Biotechnology markets. With the launch of Thomson PharmaSM, which integrates this content into a customizable workflow solution, we are re-engineering the drug development process.
Current trends indicate that key departments and teams within organizations have overlapping data requirements, but need to process that data in a variety of different ways. This data is much easier to access and share if it's available through one integrated solution.
Thomson Pharma integrates the best of the drug, intellectual property, literature and news, company, target, chemistry, and sequencing content owned by Thomson in a single solution. It enables professionals working at all stages of the drug development pipeline, from clinical researchers and chemists to competitive intelligence and licensing and business development professionals, to annotate and share a common source of integrated information.
By combining powerful annotation and file sharing features with premium content, Thomson Pharma encourages collaboration, enhances communication, and expedites decision-making across departments and enhances an organization's ability to innovate, work faster and smarter, and attain outstanding research and business results.
Thomson Pharma
can help your organization to:
To find out more, visit: www.thomsonpharma.com
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.